PCM
PRQR icon

Penserra Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Penserra Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-426
Closed -$2K – 1114
2020
Q3 		$2K Buy
+426
New +$2.23K ﹤0.01% 908

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Penserra Capital Management's PRQR Position: Q4 2020 in Review

Penserra Capital Management sold out of ProQR Therapeutics (PRQR) in Q4 2020, closing a stake of 426 shares — an estimated $2K sold.

Penserra Capital Management first reported a position in PRQR in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2020.

  • Penserra Capital Management reported no remaining ProQR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 426 ProQR Therapeutics shares in Q4 2020, an estimated $2K.
  • Penserra Capital Management first reported a position in ProQR Therapeutics in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's ProQR Therapeutics position peaked at $2K in Q3 2020.
  • 46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.